Integra LifeSciences Holdings Corporation reported $380.8 million in sales and $8.15 million in operating loss for the quarter ending September 30, 2024, which beat both Wall Street’s expectations and management’s guidance.
Stuart Essig, Integra LifeSciences’ executive chairman, Jan De Witte, president and CEO and Lea Knight, CFO presented Integra’s third quarter earnings report to Wall Street analysts.
Subscribe to continue reading
- Unlimited access to our content and archive
- Exclusive access to our newsletter
- Join the Conversation! Exclusive access to article comments.
